Bio-Path Holdings to Present Data at the 2017 AACR Annual Meeting
March 10 2017 - 8:00AM
Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company
leveraging its proprietary DNAbilize™ liposomal delivery and
antisense technology to develop a portfolio of targeted nucleic
acid cancer drugs, today announced an upcoming poster presentation
at the 2017 American Association for Cancer Research (AACR)
Annual Meeting, taking place from April 1-5, 2017 in Washington
D.C. Dr. Ana Tari Ashizawa, Director of Research at Bio-Path,
will present preclinical data of BP1002 (Liposomal Bcl2 antisense),
the Company’s second drug candidate, for the treatment of
aggressive non-Hodgkin's lymphoma.
Details for the poster presentation are as
follows:
Date: Wednesday, April 5,
2017Presentation Time: 8:00 am – 12:00 pm Eastern
TimeLocation: Walter E. Washington Convention
CenterSession: Gene and Vector Based Therapy,
Section 3Abstract: 5091Title:
“Activity of Bcl-2 antisense therapeutic in aggressive
non-Hodgkin's lymphoma” (Link to abstract)
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company focused on developing
therapeutic products utilizing DNAbilize™, its proprietary
liposomal delivery and antisense technology, to systemically
distribute nucleic acid drugs throughout the human body with a
simple intravenous transfusion. Bio-Path’s lead product candidate,
prexigebersen (BP1001, liposomal Grb2 antisense), is in a Phase II
study for blood cancers and in preclinical studies for solid
tumors. Bio-Path’s second drug candidate, also a liposomal
antisense drug, is ready for the clinic where it will be evaluated
in lymphoma and solid tumors.
For more information, please visit the Company's website at
http://www.biopathholdings.com.
Contact Information:
Investors
Will O’Connor
Stern Investor Relations, Inc.
212-362-1200
will@sternir.com
Doug Morris
Investor Relations
Bio-Path Holdings, Inc.
832-742-1369
Bio Path (NASDAQ:BPTH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bio Path (NASDAQ:BPTH)
Historical Stock Chart
From Apr 2023 to Apr 2024